litlas
Log inCreate account

Frederick L. Locke

Active 1990–2025

175
Papers
31,246
Citations
61
h-index
157
i10-index

Citations

Citations per year for Frederick L. Locke1990: 4 citations1991: 1 citations1992: 4 citations1993: 3 citations1995: 1 citations1996: 1 citations1997: 2 citations1998: 1 citations2001: 3 citations2003: 1 citations2005: 1 citations2006: 2 citations2013: 4 citations2014: 11 citations2015: 5 citations2016: 4 citations2017: 27 citations2018: 184 citations2019: 776 citations2020: 1,545 citations2021: 2,073 citations2022: 2,130 citations2023: 2,011 citations2024: 3,418 citations2025: 1,851 citations2026: 47 citations1994: no citations, so this year is not shown1999–2000: no citations, so these years are not shown2002: no citations, so this year is not shown2004: no citations, so this year is not shown2007–2012: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,444 citing papers, 30.6% of this breakdownChina: 1,322 citing papers, 11.7% of this breakdownGermany: 787 citing papers, 7% of this breakdownUnited Kingdom: 568 citing papers, 5% of this breakdownItaly: 547 citing papers, 4.9% of this breakdownFrance: 509 citing papers, 4.5% of this breakdownSpain: 440 citing papers, 3.9% of this breakdownCanada: 340 citing papers, 3% of this breakdownAustralia: 286 citing papers, 2.5% of this breakdownSwitzerland: 278 citing papers, 2.5% of this breakdownNetherlands: 257 citing papers, 2.3% of this breakdownJapan: 186 citing papers, 1.7% of this breakdown
0%30.6%Other 20.4%

Institutions

Fields

  • Medicine88.6%
  • Biochemistry, Genetics and Molecular Biology5.1%
  • Immunology and Microbiology4.3%
  • Engineering0.8%
  • Computer Science0.3%
  • Neuroscience0.2%
  • Other0.7%

Topics

  • CAR-T cell therapy research26%
  • Virus-based gene therapy research6%
  • Immune Cell Function and Interaction5.4%
  • Lymphoma Diagnosis and Treatment5.2%
  • Nanowire Synthesis and Applications4.2%
  • Cancer Immunotherapy and Biomarkers4%
  • Other49.2%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    Authors: Daniel W. Lee, Bianca Santomasso, Frederick L. Locke, Armin Ghobadi, Cameron J. Turtle, Jennifer N. Brudno, Marcela V. Maus, Jae H. Park, Elena Mead, Steven Z. Pavletic, William Y. Go, Lamis Eldjerou, Rebecca Gardner, Noelle V. Frey, Kevin J. Curran, Karl S. Peggs, Marcelo C. Pasquini, John F. DiPersio, Marcel R.M. van den Brink, Krishna V. Komanduri, Stephan A. Grupp, Sattva S. Neelapu - Biology of Blood and Marrow Transplantation 2018 cited by 3,445

  3. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    Authors: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 cited by 1,520

  4. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 cited by 1,823

  5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  6. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Authors: Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall - Nature Reviews Clinical Oncology 2017 cited by 2,380

  7. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke - Journal of Clinical Oncology 2020 cited by 786

  8. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    Authors: Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, David B. Miklos, Miguel‐Angel Perales, Armin Ghobadi, Aaron P. Rapoport, Anna Sureda, Caron A. Jacobson, Umar Farooq, Tom van Meerten, Matthew L. Ulrickson, Mahmoud Elsawy, Lori A. Leslie, Sridhar Chaganti, Michael Dickinson, Kathleen Dorritie, Patrick M. Reagan, Joseph P. McGuirk, Kevin Song, Peter A. Riedell, Monique C. Minnema, Yin Yang, Saran Vardhanabhuti, Simone Filosto, Paul Cheng, Shilpa Shahani, Marco Schupp, Christina To, Frederick L. Locke - New England Journal of Medicine 2023 cited by 410

  9. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

    Authors: Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap Jan Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John A. Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel‐Angel Perales - Nature Medicine 2024 cited by 196

  10. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

    Authors: Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Eva Hoster, Carolina Berger, Liv Jentzsch, Dimitrios Mougiakakos, Lisa Frölich, Josephine Ackermann, Veit Bücklein, Viktoria Blumenberg, Christian Schmidt, Laurent Jallades, Boris Fehse, Christoph Faul, Philipp Karschnia, Oliver Weigert, Martin Dreyling, Frederick L. Locke, Michael von Bergwelt‐Baildon, Andréas Mackensen, Wolfgang Bethge, Francis Ayuk, Emmanuel Bachy, Gilles Salles, Michael D. Jain, Marion Subklewe - Blood 2021 cited by 441

  11. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    Authors: Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot - Blood Advances 2020 cited by 455

  12. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

    Authors: Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin, Leyla Shune, Alexandria M Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aimaz Afrough, Ankit Kansagra, Peter M. Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph P. McGuirk, Frederick L. Locke, Krina K. Patel - Journal of Clinical Oncology 2023 cited by 279

  13. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

    Authors: Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir, Viktoria Blumenberg, Maria‐Luisa Schubert, Uria Mor, Matthias Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia‐Chi Chang, Lauren McDaniel, Ivonne I. Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphaël Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Reetakshi Arora, Michael Wang, Joel G. Turner, Meghan Menges, Melanie J. Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Müller‐Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav - Nature Medicine 2023 cited by 226

  14. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  15. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    Authors: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 cited by 318

  16. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

    Authors: Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia Carpio, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Frederick L. Locke, Michael von Bergwelt‐Baildon, Andréas Mackensen, Wolfgang Bethge, Pere Barba, Michael D. Jain, Marion Subklewe - Journal for ImmunoTherapy of Cancer 2022 cited by 191

  17. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

    Authors: Caron A. Jacobson, Frederick L. Locke, Long Ma, Julius Asubonteng, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel‐Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Michele Hooper, Jun Kawashima, Hairong Xu, Marcelo C. Pasquini - Transplantation and Cellular Therapy 2022 cited by 181

  18. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

    Authors: Marcelo C. Pasquini, Zhen‐Huan Hu, Kevin J. Curran, Theodore W. Laetsch, Frederick L. Locke, Rayne H. Rouce, Michael A. Pulsipher, Christine L. Phillips, Amy K. Keating, Matthew J. Frigault, Dana Salzberg, Samantha Jaglowski, Joshua Sasine, Joseph Rosenthal, Monalisa Ghosh, Daniel J. Landsburg, Steven Margossian, Paul L. Martin, Manali Kamdar, Peiman Hematti, Sarah Nikiforow, Cameron J. Turtle, Miguel‐Angel Perales, Patricia Steinert, Mary M. Horowitz, Amy Moskop, Lida Pacaud, Lan Yi, Raghav Chawla, Eric Bleickardt, Stephan A. Grupp - Blood Advances 2020 cited by 434

  19. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    Authors: Nathalie Scholler, Régis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jaeyeon Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon - Nature Medicine 2022 cited by 198

  20. How I Treat Cytopenias after CAR T-cell Therapy

    Authors: Tania Jain, Timothy S. Olson, Frederick L. Locke - Blood 2023 cited by 129

  21. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

    Authors: Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel Krivenko, Victoria S. Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chávez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien Liu, Javier Pinilla‐Ibarz, Bijal Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai Dholaria, Michael D. Jain, Frederick L. Locke - Haematologica 2020 cited by 271

  22. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

    Authors: Michael D. Jain, Hua Zhao, Xuefeng Wang, Reginald Atkins, Meghan Menges, Kayla Reid, Kristen Spitler, Rawan Faramand, Christina A. Bachmeier, Erin Dean, Biwei Cao, Julio C. Chávez, Bijal Shah, Aleksandr Lazaryan, Taiga Nishihori, Mohammed Hussaini, Ricardo J. Gonzalez, John E. Mullinax, Paulo C. Rodrı́guez, José R. Conejo-García, Claudio Anasetti, Marco L. Davila, Frederick L. Locke - Blood 2021 cited by 292

  23. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

    Authors: Marcela V. Maus, S. Alexander, Michael R. Bishop, Jennifer N. Brudno, Colleen Callahan, Marco L. Davila, Claudia Diamonte, Jörg Dietrich, Julie C. Fitzgerald, Matthew J. Frigault, Terry J. Fry, Jennifer Holter‐Chakrabarty, Krishna V. Komanduri, Daniel W Lee, Frederick L. Locke, Shannon L. Maude, Philip L. McCarthy, Elena Mead, Sattva S. Neelapu, Tomas G. Neilan, Bianca Santomasso, Elizabeth J. Shpall, David T. Teachey, Cameron J. Turtle, Tom Whitehead, Stephan A. Grupp - Journal for ImmunoTherapy of Cancer 2020 cited by 269

  24. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    Authors: Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier Muñoz, Saurabh Dahiya, Amer Beitinjaneh, Miriam T. Jacobs, Joseph P. McGuirk, Julie M. Vose, André Goy, Charalambos Andreadis, Brian T. Hill, Kathleen Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros J. Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael Wang, Michael D. Jain - Journal of Clinical Oncology 2023 cited by 176